Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Maurel, Marine
Howard, Jennifer
Kissling, Esther
Pozo, Francisco
Pérez-Gimeno, Gloria
Buda, Silke
Sève, Noémie
McKenna, Adele
Meijer, Adam
Rodrigues, Ana Paula
Martínez-Baz, Iván
Mlinarić, Ivan
Latorre-Margalef, Neus
Túri, Gergő
Lazăr, Mihaela
Mazagatos, Clara
Echeverria, Aitziber
Abela, Stephen
Bourgeois, Marc
Machado, Ausenda
Dürrwald, Ralf
Petrović, Goranka
Beatrix
Oroszi, Beatrix
Jancoriene, Ligita
Marin, Alexandru
Husa, Petr
Duffy, Roisin
Dijkstra, Frederika
Gallardo García, Virtudes
Goerlitz, Luise
Enouf, Vincent
Bennett, Charlene
Hooiveld, Mariëtte
Guiomar, Raquel
Trobajo-Sanmartín, Camino
Višekruna Vučina, Vesna
Samuelsson Hagey, Tove
Lameiras Azevedo, Ana Sofía
Castilla, Jesús
Xuereb, Gerd
Delaere, Bénédicte
Gómez, Verónica
Tolksdorf, Kristin
Bacci, Sabrina
Nicolay, Nathalie
Kaczmarek, Marlena
Rose, Angela M. C.
on behalf of the European IVE group
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: −3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: −32 to 43), respectively.
